Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics.

Autor:	Prignano F; Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy - francesca.prignano@unifi.it., Pescitelli L; Unit of Dermatology, San Giuseppe Hospital, Empoli, Florence, Italy., Trovato E; Section of Dermatology, Department of Medical, Surgical and Neurological Science, S. Maria alle Scotte Hospital, University of Siena, Siena, Italy., DI Cesare A; Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy., Cuccia A; Unit of Dermatology, San Donato Hospital, Arezzo, Italy., Mazzatenta C; Unit of Dermatology, Hospital of Campo di Marte, Lucca, Italy., Pellegrino M; Unit of Dermatology, Misericordia Hospital, Grosseto, Italy., Marsili F; Unit of Dermatology, Versilia Hospital, Lido di Camaiore, Lucca, Italy., Castelli A; Unit of Dermatology, San Donato Hospital, Arezzo, Italy., Brandini L; Unit of Dermatology, San Giuseppe Hospital, Empoli, Florence, Italy., Niccoli MC; Unit of Dermatology, Hospital of Prato, Prato, Italy., Taviti F; Unit of Dermatology, Hospital of Prato, Prato, Italy., Ricceri F; Unit of Dermatology, San Donato Hospital, Arezzo, Italy., Panduri S; Department of Dermatology, University of Pisa, Pisa, Italy., Buggiani G; Unit of Dermatology, San Giuseppe Hospital, Empoli, Florence, Italy., Ghilardi A; Unit of Dermatology, Hospital of Campo di Marte, Lucca, Italy., Rubegni P; Section of Dermatology, Department of Medical, Surgical and Neurological Science, S. Maria alle Scotte Hospital, University of Siena, Siena, Italy., Romanelli M; Department of Dermatology, University of Pisa, Pisa, Italy., Pimpinelli N; Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy.
Jazyk:	angličtina
Zdroj:	Italian journal of dermatology and venereology [Ital J Dermatol Venerol] 2022 Dec; Vol. 157 (6), pp. 469-479. Date of Electronic Publication: 2022 Jul 05.
DOI:	10.23736/S2784-8671.22.07355-8
Abstrakt:	Psoriasis is a common chronic skin disease characterized by a worldwide distribution and a natural tendency towards progression. According to the many clinical forms, the extension of the disease and the many comorbidities, almost the 20% of the patients require a systemic treatment. Biologics have greatly changed the ongoing of psoriasis and the quality of life of psoriasis patients. After the anti-TNF-alpha, which were the first biologics in use for psoriasis, the improvement in knowledge of the pathogenetic mechanisms underlying the disease has led to the development of a series of more specific therapies for psoriasis. This "second generation" of biologics includes the interleukin (IL)-12/23 inhibitor ustekinumab, IL-17 inhibitors (secukinumab and ixekizumab), the IL-17 receptor A (IL-17RA) antagonist brodalumab, and the IL-23 inhibitors guselkumab, risankizumab and tildrakizumab. This study represents an update of the Tuscany consensus focused on the use of new drugs, such as anti-IL-17 and anti-IL-23 in moderate-to-severe psoriasis and their correct place in therapy according to specific clinical requests and in full respect of the current financial restrictions.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu